Shares of ImmunoPrecise Antibodies Ltd. (IPA) skyrocketed 138% on the news that results from its TATX-03 PolyTope Therapy, which is a four monoclonal antibody cocktail, displayed potent neutralizing activity against the SARS-CoV-2 Delta variant in in vitro pseudovirus assays. Shares closed at $13.22 on July 22.
IPA engages in the provision of integrated antibody solutions. The company had previously announced that its TATX-03 showed strong ability in reducing the viral load in vivo and potently neutralized pseudovirus of Alpha and Beta variants in vitro. (See ImmunoPrecise Antibodies stock charts on TipRanks)
IPA published its scientific paper “Cornering an Ever-Evolving Coronavirus: TATX-03 a fully human synergistic multi-antibody cocktail targeting the SARS-CoV-2 Spike Protein with in vivo efficacy”.
The company stated that additional evaluation of virus neutralization potency in an in vitro pseudovirus-based assay revealed that the antibody cocktail is not affected by the rapidly spreading Delta variant.
The company also stated that the binding data combined with the maintained neutralization potency of IPA’s TATX-03 to variants of concern, Alpha, Beta, and Kappa is in line with the companies expectations that multi-membered antibody cocktails are more viable than the traditional ones.
Dr. Ilse Roodink, IPA’s Chief Scientific Officer and Global Program Director for COVID Research said, “Our TATX-03 cocktail is rationally designed for broad epitope coverage relying on multiple antibodies, which have shown in pre-clinical studies to work synergistically together, to reduce the risk of mutagenic escape, and have the potential to reduce the risk of new variants.”
According to TipRanks’ Smart Score system, ImmunoPrecise Antibodies gets a 6 out of 10, which indicates that the stock is likely to perform in line with market averages.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.